Archive

Generic drug tariffs could raise US medicine costs, disrupt global supply chains and pressure manufacturers to move production to America.

Medicine safety is in focus as the iDexis court case raises questions about compounding, regulation and patient monitoring.

PEPFAR cuts have been linked to a 45% decline in South African children receiving HIV treatment at US-supported healthcare sites.

Fake medical certificates are driving sick leave abuse in South Africa, costing employers through absenteeism, fraud and lost productivity.

Aspen Semaglutide Canada gains Health Canada approval, but API supply problems could delay the generic’s commercial launch.

The Extensior South Africa launch on 27 July, offering patients a lower-cost, authorised semaglutide treatment for type 2 diabetes.

Ambulance tariff negotiations could help private emergency service providers address low payments, cash-flow pressure and market contraction.

Learn how Discovery Health aims for robust membership growth amid challenges posed by churn and an aging member pool.

Medscheme Bonitas Court Bid withdrawal allows the CMS to resume its forensic probe into disputed Bonitas procurement processes.

Illicit medicines in South Africa are rising, prompting Sahpra to launch a national campaign on counterfeit drugs and unsafe online sellers.

Sun Pharma’s Generic Semaglutide is now available in South Africa. Explore this new treatment option for type 2 diabetes.